Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | HTR7 | P34969 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13698469 | 0.84 | SMN1; SMN2 (0.60) | ALDH1A1LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL6506137 | 0.79 | NOTUM (0.61) | ALDH1A1LMNAMAPK1USP2HTT | |
| SCHEMBL6258508 | 0.77 | POLB (0.70) | ALDH1A1LMNAMAPK1USP2HTT | |
| SCHEMBL5231536 | 0.77 | LMNA (0.70) | ALDH1A1LMNAMAPK1USP2HTT | |
| SCHEMBL10762915 | 0.77 | ALDH1A1 (0.64) | ALDH1A1LMNAMAPK1HTTRAB9A | |
| SCHEMBL26706279 | 0.76 | ALDH1A1 (0.76) | ALDH1A1LMNAHTTSMN1; SMN2ALOX12 | |
| SCHEMBL26706278 | 0.76 | ALDH1A1 (0.76) | ALDH1A1LMNAHTTSMN1; SMN2ALOX12 | |
| SCHEMBL5234744 | 0.76 | ALDH1A1 (0.67) | ALDH1A1LMNAMAPK1USP2HTT | |
| SCHEMBL10761054 | 0.76 | ALDH1A1 (0.67) | ALDH1A1LMNAMAPK1USP2HTT | |
| SCHEMBL3762865 | 0.76 | POLB (0.61) | ALDH1A1SMN1; SMN2MEN1KMT2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239873-A1 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | BLANCO MIGUEL GARCIA-GUZMAN | 2009-09-24 | — | — | US | disclosed |
| US-20090239873-A1 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | BLANCO MIGUEL GARCIA-GUZMAN | 2009-09-24 | — | — | US | disclosed |
| US-7563795-B2 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563795-B2 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239873-A1 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | ALDH1A1 2270/4885LMNA 4305/4885MAPK1 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.